Search

Your selection

None

Filter by content type

Filter by content year

News

FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate

August 2, 2021 - … higher serum antibodies than construct expressing both S and N in NHP study Phase II clinical trial with S-only candidate to begin in 2H21 Development of this and other S-only constructs will proceed in parallel with … administered by tablet, announced today that the U.S. Food and Drug Administration has cleared Vaxart's Investigational …
News

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

April 30, 2024 - … 2024 Earnings Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide … rose on average 4.0 fold for the G1.1 virus strain and 6.0 fold for the GII.4 virus strain in the breast milk of … were no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity. “This is an important …
News

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

December 1, 2022 - … in Breastfeeding Mothers December 1, 2022 General Funding and support provided by Bill & Melinda Gates Foundation   … can be challenging. Passive transfer of antibodies from mother to infant that are induced in milk may protect … can be challenging. Passive transfer of antibodies from mother to infant that are induced in milk may protect …
News

Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

February 24, 2022 - … Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates Vaxart’s … Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates February … generated antibodies to the original COVID-19 virus strain and to the beta, delta, alpha and gamma variants of …
News

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

May 19, 2022 - … in hamsters showed both a decrease in infectious  virus and in transmission Phase 1 data measuring cross-reactivity … other vaccine candidate, the one targeting both the S and N proteins, could be effective against a range of diverse … The study compared various measures of immunity and viral shedding in hamster cohorts immunized with Vaxart’s …
News

Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

October 6, 2021 - … of 96 U.S. subjects, split evenly between COVID-19 naïve and mRNA vaccinated subjects, later this month.  The … important milestone in the development of the first and only COVID-19 oral tablet vaccine that has reached this … impact the world's response to the COVID-19 pandemic and to improve global public health. It can be easier and …
News

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024 - … Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results May 13, 2024 … meeting with the FDA in mid-2024 to evaluate clinical data and discuss next steps for its norovirus program Conference …
News

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

November 2, 2023 - … of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN … 21 million people in the United States each year, and 15% of children under age 5 contract norovirus annually. … study is designed to evaluate the safety, tolerability, and immunogenicity of orally administered bivalent GI.1/GII.4 …
News

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

December 21, 2023 - … VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart’s … to protect their children against this highly contagious – and potentially lethal -- virus. We look forward to … 21 million people in the United States each year, and 15% of children under age 5 contract norovirus annually. …
News

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

September 1, 2022 - … Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine … Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine … September 1, 2022 General —   Study met primary safety and secondary immunogenicity endpoints — — Boosted serum …
Scroll to Top